Edward Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1461266/publications.pdf

Version: 2024-02-01

448610 340414 1,789 61 19 39 citations h-index g-index papers 61 61 61 1691 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	3.7	79
2	Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2022, 33, 510-517.e1.	0.2	7
3	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nature Medicine, 2022, 28, 626-629.	15.2	12
4	Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. European Radiology, 2022, 32, 6493-6503.	2.3	5
5	Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. The Lancet Gastroenterology and Hepatology, 2022, 7, 843-850.	3.7	42
6	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study., 2022, 10, e004205.		26
7	Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncology Practice, 2021, 17, e266-e277.	1.4	12
8	Single-System Experience With Outpatient Transradial Uterine Artery Embolization: Safety, Feasibility, Outcomes, and Early Rates of Return. American Journal of Roentgenology, 2021, 216, 975-980.	1.0	7
9	A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery, 2021, 169, 1044-1051.	1.0	18
10	Yttriumâ€90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology, 2021, 74, 2342-2352.	3.6	215
11	Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma. Cancer Research, 2021, 81, CT182-CT182.	0.4	3
12	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020). Gastroenterology, 2021, 161, 879-898.	0.6	123
13	Use of yttrium-90 (Y90) glass microspheres (TheraSphere) as neoadjuvant to transplantation/resection in hepatocellular carcinoma: Analyses from the LEGACY study Journal of Clinical Oncology, 2021, 39, 300-300.	0.8	4
14	Early effect of 90Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. European Radiology, 2021, 31, 5791-5801.	2.3	6
15	Radiation Segmentectomy. Seminars in Interventional Radiology, 2021, 38, 425-431.	0.3	3
16	Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT. CardioVascular and Interventional Radiology, 2020, 43, 295-301.	0.9	10
17	Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 1729-1738.e1.	0.2	27
18	Assessment of Hepatocellular Carcinoma Response to ⟨sup⟩90⟨/sup⟩Y Radioembolization Using Dynamic Contrast Material–enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. Radiology Imaging Cancer, 2020, 2, e190094.	0.7	15

#	Article	IF	CITATIONS
19	Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization. International Journal of Radiation Oncology Biology Physics, 2019, 105, 968-976.	0.4	14
20	Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. Hpb, 2019, 21, 1497-1504.	0.1	30
21	Prediction of hepatocellular carcinoma response to 90Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results. Cancer Imaging, 2019, 19, 29.	1.2	13
22	Retrieval of Inferior Vena Cava Filters Temporarily Placed in a Suprarenal Position: A Review of 13 Patients. Vascular and Endovascular Surgery, 2019, 53, 446-451.	0.3	3
23	Yttrium-90 Complications: Prevention and Management. Techniques in Vascular and Interventional Radiology, 2019, 22, 87-92.	0.4	10
24	Patient Experience and Preference in Transradial versus Transfemoral Access during Transarterial Radioembolization: A Randomized Single-Center Trial. Journal of Vascular and Interventional Radiology, 2019, 30, 414-420.	0.2	46
25	The Role of Radioembolization in Bridging and Downstaging Hepatocellular Carcinoma to Curative Therapy. Seminars in Nuclear Medicine, 2019, 49, 189-196.	2.5	18
26	Safety and Outcomes of Transradial Access in Patients with International Normalized Ratio 1.5 or above. Journal of Vascular and Interventional Radiology, 2018, 29, 383-388.	0.2	15
27	Outcomes of radioembolization for unresectable hepatocellular carcinoma in patients with marginal functional hepatic reserve. Clinical Imaging, 2018, 47, 34-40.	0.8	3
28	Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, 30-37.e2.	0.2	51
29	Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 734-740.	0.6	22
30	Comparison of PET/CT and PET/MR imaging and dosimetry of yttrium-90 (90Y) in patients with unresectable hepatic tumors who have received intra-arterial radioembolization therapy with 90Y microspheres. EJNMMI Physics, 2018, 5, 23.	1.3	9
31	Patient Radiation Exposure in Transradial versus Transfemoral Yttrium-90 Radioembolization: A Retrospective Propensity Score–Matched Analysis. Journal of Vascular and Interventional Radiology, 2018, 29, 936-942.	0.2	11
32	Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques. Journal of Nuclear Medicine, 2018, 59, 1649-1654.	2.8	11
33	Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience. Journal of Vascular and Interventional Radiology, 2018, 29, 920-926.	0.2	13
34	Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy. Abdominal Radiology, 2017, 42, 1685-1694.	1.0	37
35	Transfemoral Filter Eversion Technique following Unsuccessful Retrieval of Option Inferior Vena Cava Filters: A Single Center Experience. Journal of Vascular and Interventional Radiology, 2017, 28, 889-894.	0.2	13
36	Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Seminars in Interventional Radiology, 2017, 34, 109-115.	0.3	12

#	Article	IF	CITATIONS
37	Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 161-168.	0.7	17
38	Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study. Radiology, 2017, 283, 895-905.	3.6	75
39	Imaging of Hepatocellular Carcinoma Response After ⁹⁰ Y Radioembolization. American Journal of Roentgenology, 2017, 209, W263-W276.	1.0	29
40	Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel. European Radiology, 2017, 27, 4923-4930.	2.3	8
41	Transradial access for Visceral Endovascular Interventions in Morbidly Obese Patients: Safety and Feasibility. Journal of Vascular Access, 2016, 17, 256-260.	0.5	18
42	Radiation dose reduction utilizing noise reduction technology during uterine artery embolization: a pilot study. Clinical Imaging, 2016, 40, 378-381.	0.8	3
43	The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. Hpb, 2016, 18, 411-418.	0.1	6
44	Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. Journal of Vascular and Interventional Radiology, 2016, 27, 812-821.e2.	0.2	44
45	Transradial Approach for Hepatic Radioembolization: Initial Results and Technique. American Journal of Roentgenology, 2016, 207, 1112-1121.	1.0	44
46	Transjugular Intrahepatic Portosystemic Shunt Flow Reduction with Adjustable Polytetrafluoroethylene-Covered Balloon-Expandable Stents Using the "Sheath Control―Technique. CardioVascular and Interventional Radiology, 2016, 39, 935-939.	0.9	15
47	Transradial Approach for Noncoronary Interventions: A Single-Center Review of Safety and Feasibility in the First 1,500 Cases. Journal of Vascular and Interventional Radiology, 2016, 27, 159-166.	0.2	122
48	Reply. Hepatology, 2015, 61, 407-407.	3.6	4
49	GI hemorrhage arising from splenic artery: intraprocedure cone-beam CT as problem-solving tool to aide in safe catheterization of offending vessel. Clinical Imaging, 2015, 39, 928-930.	0.8	5
50	Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. Journal of Vascular and Interventional Radiology, 2015, 26, 1630-1638.	0.2	9
51	Percutaneous Mesocaval Shunt Creation in a Patient with Chronic Portal and Superior Mesenteric Vein Thrombosis. CardioVascular and Interventional Radiology, 2015, 38, 1316-1319.	0.9	14
52	Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology, 2014, 60, 192-201.	3.6	237
53	CT-Guided Liver Biopsy With Electromagnetic Tracking: Results From a Single-Center Prospective Randomized Controlled Trial. American Journal of Roentgenology, 2014, 203, W715-W723.	1.0	14
54	Histological Changes in Nontumoral Liver Secondary to Radioembolization of Hepatocellular Carcinoma with Yttrium 90-impregnated Microspheres: Report of Two Cases. Seminars in Liver Disease, 2014, 34, 465-468.	1.8	6

#	Article	IF	CITATIONS
55	Portal Vein Embolization before Right Hepatectomy or Extended Right Hepatectomy Using Sodium Tetradecyl Sulfate Foam: Technique and Initial Results. Journal of Vascular and Interventional Radiology, 2014, 25, 1045-1053.	0.2	30
56	Prospective, Randomized Study of Coil Embolization versus Surefire Infusion System during Yttrium-90 Radioembolization with Resin Microspheres. Journal of Vascular and Interventional Radiology, 2014, 25, 1709-1716.	0.2	19
57	Revascularization for Critical Limb Ischemia Using the SpiderFX Embolic Protection Device in the Below-the-Knee Circulation: Initial Results. Journal of Vascular and Interventional Radiology, 2014, 25, 1533-1538.	0.2	6
58	Uterine Artery Embolization Using a Transradial Approach: Initial Experience and Technique. Journal of Vascular and Interventional Radiology, 2014, 25, 443-447.	0.2	82
59	Percutaneous Microwave Ablation of Renal Tumors Using a Gas-Cooled 2.4-GHz Probe: Technique and Initial Results. Journal of Vascular and Interventional Radiology, 2014, 25, 448-453.	0.2	22
60	Survival following Y90 radioembolization for neuroendocrine tumor liver metastases: A retrospective, single-center analysis Journal of Clinical Oncology, 2014, 32, e15166-e15166.	0.8	2
61	Emergent Embolization of Arterial Bleeding after Vacuum-Assisted Breast Biopsy. CardioVascular and Interventional Radiology, 2012, 35, 194-197.	0.9	13